The invention relates generally to implants for vertebral body or functional spinal unit replacement. More particularly, the invention relates to such implants that have a bioactive surface roughening on at least bone-contacting portions of the sides, and methods for implanting such implants. The bioactive surface roughening promotes osteogenesis and osteointegration about the lateral surfaces of the implant.
Various publications, including patents, published applications, technical articles and scholarly articles are cited throughout the specification. Each of these cited publications is incorporated by reference, in its entirety and for all purposes, in this document.
The spinal column includes vertebrae and discs stacked together, and an interior pathway through which the spinal cord extends. The vertebrae provide the support and structure of the spine. The discs, located between the vertebrae, act as cushions and contribute to the flexibility and motion of the spinal column. Two adjacent vertebrae and an intervening disc are known in the art as a functional spinal unit or spinal motion segment.
In case of damage or degenerative disease, including cancer, to the vertebrae or to a functional spinal unit, the injured vertebrae or unit may be removed, in part or in total. The removal procedure is known in the art as a corpectomy. An implant is then inserted in place of the removed vertebrae, unit, or part thereof. Given the large gap that the implant spans, and given that corpectomy procedures typically do not retain much, if any, intervening bone between extant vertebrae, such implant designs generally have not been geared toward encapsulation of the implant with new bone. In addition, new bone growth on and near the implant is often slow, insufficient, and/or uneven, which may lengthen the healing process or diminish the ultimate effectiveness of the procedure. Therefore, it is desirable to enhance bone growth on and around the implant, particularly where the implant stands in place of removed bone material.
The disclosure features implants, which are implanted into a channel cut through the end plate bone of a vertebrae, in order to replace the removed bone and/or to replace a functional spinal unit. The implants comprise a body that preferably is generally oval-shaped in transverse cross section, and have a height (from the bottom surface to the top surface) that is substantially the same as the height of the vertebral end plate, the vertebral body, or the functional spinal unit the implant replaces. The implants comprise a top surface, a bottom surface, opposing lateral sides, and opposing anterior and posterior sides, with a substantially hollow center in the interior of the implant. The implants also comprise a single vertical aperture, which extends from the top surface to the bottom surface, and is in communication with the substantially hollow center. The vertical aperture has maximum width at its center, and defines a transverse rim on the top surface and on the bottom surface. The transverse rim has a posterior thickness greater than an anterior thickness, and has a blunt and radiused portion along the top of each lateral side and the top of the posterior side. The blunt and radiused portion may taper, particularly at the posterior side. The implants also comprise a bioactive surface roughening. The bioactive roughened surface comprises macro-, micro-, and nano-scale structures capable of facilitating bone growth. This roughening is present on at least the portion of the transverse rim that is not blunt and radiused, the posterior side (substantially all of the posterior side between the top surface and the bottom surface), and at least a portion of each opposing lateral side (between the top surface and the bottom surface), which portion of the lateral side may extend part-way or substantially all the way between the posterior side and the anterior side. Preferably, the blunt and radiused portion does not include any bioactive roughened surface, and the body has a sharp edge at the junction of the anterior side and the top surface and at the junction of the anterior side and the bottom surface. The body may also have a sharp edge at the junction of the anterior side of the single vertical aperture and the top surface, and at the junction of the anterior side of the single vertical aperture and the bottom surface. The implant may comprise a lordotic angle.
The implant may be constructed of any suitable material, including a metal or polymer, or a composite of a metal and polymer. The metal may comprise titanium or an alloy thereof. The polymer may comprise polyetherether-ketone or ultra-high molecular weight polyethylene.
In some aspects, the implant comprises a bone graft material in the substantially hollow center. The bone graft material may comprise cancellous autograft bone, allograft bone, demineralized bone matrix (DBM), porous synthetic bone graft substitute, bone morphogenic protein (BMP), or combinations thereof. In some aspects, the implant comprises one or more screw apertures extending through the anterior side and top surface and through the anterior side and bottom surface.
The implant preferably comprises one or more transverse apertures through the sidewalls of the body, which apertures are in communication with the substantially hollow center. The one or more transverse apertures may be present on the anterior side, the posterior side, and/or one or more of the opposing lateral sides. One or more of the transverse apertures may comprise one or more intermediate walls that divide the transverse apertures. The one or more intermediate walls may be vertically-oriented, horizontally-oriented, and/or diagonally-oriented. The intermediate walls may, but need not, divide the transverse apertures into equally sized transverse apertures.
The disclosure also features methods. The methods comprise implanting an implant, such as any implant described or exemplified herein into a channel through a vertebral body such that the bioactive roughened surface on the posterior side, anterior side, and/or opposing lateral side(s) contacts the remaining vertebral bone that at least partially surrounds the channel. If the implant includes a transverse aperture, the methods may further comprise adding or loading a bone graft material into the substantially hollow center, for example, through the transverse aperture. Preferably, the bone graft material extends through the transverse aperture and makes contact with the vertebral bone that surrounds the channel and the implant inserted into the channel.
The invention is best understood from the following detailed description when read in connection with the accompanying drawings, in which like reference numbers refer to like elements throughout the various figures. It is emphasized that, according to common practice, the various features of the drawings are not to scale. On the contrary, the dimensions of the various features are arbitrarily expanded or reduced for clarity. Included in the drawings are the following figures in which:
Various terms relating to aspects of the present disclosure are used throughout the specification and claims. Such terms are to be given their ordinary meaning in the art, unless otherwise indicated. Other specifically defined terms are to be construed in a manner consistent with the definition provided in this document.
As used throughout, the singular forms “a,” “an,” and “the” include plural referents unless expressly stated otherwise.
The terms subject and patient are used interchangeably. A patient may be any animal, including mammals such as companion animals, laboratory animals, and non-human primates. Human beings are preferred.
A functional spinal unit includes a vertebrae and the intervertebral discs between a superior and inferior vertebrae. A functional spinal unit may include a cervical functional spinal unit, a thoracic functional spinal unit, or a lumbar functional spinal unit.
Implants in accordance with certain aspects of the disclosure stand in the place of at least a portion of at least one vertebrae, including in the place of a functional spinal unit (
The implants may be made of any suitable material. Suitable materials include plastics, polymers, silicone, metals, ceramics, bone, or composites of any such materials. Suitable polymers include polyether ether ketone (PEEK) and ultra-high molecular weight polyethylene (UHMWPE), as well as urethane dimethacrylate (DUDMA)/tri-ethylene glycol dimethacrylate (TEDGMA) blended resin. Suitable metals may comprise titanium, an alloy of titanium such as an aluminum and vanadium alloy of titanium (e.g., 6-4), a nickel alloy of titanium such as nitinol, a cobalt chromium alloy, or surgical grade steel.
Referring now to the drawing, in which like reference numbers refer to like elements throughout the various figures that comprise the drawing,
Without being limited to any particular theory or mechanism of action, it is believed that the cumulative effects of at least implant composition, implant surface energy, and implant surface roughness play a major role in the biological response to, and osteointegration of an implant device. Thus, implant fixation may depend, at least in part, on the attachment and proliferation of osteoblasts and like-functioning cells upon surfaces of the implant 1. It is believed that cells attach more readily to relatively rough surfaces rather than smooth surfaces. In this manner, a surface may be bioactive due to its ability to facilitate cellular attachment and osteointegration. The roughened bioactive surface 80 may better promote the osteointegration of the implant 1. On certain faces of the implant 1, the roughened bioactive surface 80 may also better grip the vertebral endplate surfaces and inhibit implant migration of the implant 1 upon placement and seating in a patient. Accordingly, the implant 1 further includes the roughened bioactive surface 80 on one or more bone-contacting portions of the implant 1, including at least a portion of its top 10 and bottom 20 surfaces for gripping vertebral endplate bone of adjacent vertebrae that flank the implant 1, and at least a portion of one or more of the opposing lateral sides 30, anterior 40 side, and posterior 50 side.
The implant 1 includes a vertical aperture 60, which passes through the top 10 and bottom 20 surfaces, and is in communication with a substantially hollow center 66. The shape of the vertical aperture 60 may vary. For example, the shape may be substantially circular, elliptical, or D-shaped. The vertical aperture 60 preferably comprises maximal width at its center. The vertical aperture 60, in combination with the edges around the periphery of the top 10 and bottom 20 surfaces, defines a transverse rim.
The transverse rim has a generally large surface area and contacts the vertebral endplate. The transverse rim may act to better distribute contact stresses upon the implant 1, and hence minimize the risk of subsidence while maximizing contact with the apophyseal supportive bone. The transverse rim may have a variable width, including a larger posterior width than anterior width, or vice versa. It is also possible for the transverse rim to have a substantially constant width around the perimeter of the vertical aperture 60.
One or more of the anterior side 40 edges, posterior side 50 edges, and/or lateral side 30 edges of the implant 1 may be blunt, radiused, rounded and/or tapered (see, e.g.,
The vertical aperture 60 comprises a maximum width at its center. The width of the vertical aperture 60 may range from about 20% to about 80% of the distance between opposing lateral sides. In some aspects, the width ranges from about 40% to about 80% of the distance between the opposing lateral sides. In some aspects, the width ranges from about 50% to about 70% of the distance between the opposing lateral sides. In some aspects, the width ranges from about 50% to about 65% of the distance between the opposing lateral sides. In some aspects, the width ranges from about 60% to about 70% of the distance between the opposing lateral sides. In some aspects, the width ranges from about 55% to about 75% of the distance between the opposing lateral sides. In some aspects, the width ranges from about 60% to about 80% of the distance between the opposing lateral sides. In some aspects, the width is about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, or about 90% of the distance between the opposing lateral sides. Preferably, the width of the vertical aperture 60 comprises the dimension between the lateral sides 30.
The top surface 10 and bottom surface 20 may comprise a sharp, expulsion-resistant edge 8. The sharp edge 8 is preferably present at the edge of the anterior side 40, and a sharp edge 8 may also be present at the anterior edge of the vertical aperture 60 on the top surface 10 and bottom surface 20. The sharp edge 8 helps to engage vertebral endplate bone, and inhibit expulsion of the implant 1 following implantation.
The body of the implant 1 may comprise solid anterior 40, posterior 50, or lateral 30 walls. See
The implant 1 may include at least one transverse aperture 70. The at least one transverse aperture 70 may be present on one or more of the lateral sides 30 (
In some aspects, each transverse aperture 70 may be divided into at least two separate sections (e.g., 70a and 70b) by an intermediate wall 32.
In some aspects, the implant 1 comprises one or more screw apertures 46. For example, as shown in
The one or more screw apertures 46 essentially bore through the sidewalls of the implant 1 at an angle that would allow a bone screw (not shown) to pass through the implant 1 body and into adjacent bone, not unlike “toenailing” used in carpentry. The bone screw assists in affixing the implant 1 in place within the spinal column, and enhances implant 1 retention and inhibits movement and expulsion of the implant 1 after implantation. Each screw aperture 46 may comprise concave sidewalls to accommodate a screw and fixation collar, for example, the screw and fixation collar described in U.S. patent application Ser. No. 14/272,557, incorporated by reference herein.
In some aspects, the one or more screw apertures 46 and the corresponding insertion path of the screws (not shown) are positioned at an angle of about 30° to about 60° of the vertical axis of the implant 1. Angles less than about 30° or greater than about 60° may be used in some aspects. The degree of angling may be a function of the implant size or type, or of particular patient characteristics, or of the location or position of the implant 1 once implanted. In some aspects, the implant 1 comprises one or more screw apertures 46 configured for the screw to extend through the top 10 and embed in the upper vertebrae, or through the bottom 20 and embed in the lower vertebrate. The one or more screw apertures 46 may be in communication with the hollow center 66 and the vertical aperture 60 on the top 10 or bottom 20 of the implant 1, for example, as shown in
The implant 1 may comprise a lordotic angle, e.g., may be wedge-shaped to facilitate sagittal alignment. Thus, for example, the anterior side 40 of the implant 1 may comprise a height that is larger than the height of the posterior side 50, or vice versa. Alternatively, one of the lateral sides 30 of the implant 1 may comprise a height that is larger than the height of the opposing lateral side 30. The lordotic angle may closely approximate, or otherwise is substantially the same as, the angle of lordosis of the spine of the patient where the implant 1 will be implanted. The implant 1 may have a lordotic angle L about 3%, about 3.3%, about 3.5%, about 3.7%, about 4%, about 4.3%, about 4.5%, about 4.7%, or about 5% greater than the patient's angle of lordosis, though percentages greater than 5% or lesser 3% are possible.
The implant 1 may also comprise an opening 90 in the anterior side 40 (
Except for certain faces, the implant 1 surfaces have heavily rounded edges, creating a low stress contact with the end-plates. The wide rim of the top 10 and bottom 20 surfaces, in contact with the end-plates, creates a low-stress contact due to the large surface area. As well, the implant 1 has an engineered stiffness to minimize the stiffness mismatch with the vertebral body which it contacts. Generally, the implant 1 is shaped to maximize contact with the apophyseal rim of the vertebral endplates. The implant 1 is designed to be impacted between the endplates, with fixation to the endplates created by an interference fit and annular tension. Thus, the implant 1 is preferably shaped and sized to spare the vertebral endplates and leave intact the hoop stress of the endplates. A wide range of sizes are possible to capture the apophyseal rim, along with a broad width of the peripheral rim, especially in the posterior region. It is expected that such designs will lead to reduced subsidence. The implant 1 preferably allows for deflection of the endplates like a diaphragm. A bone graft material inside the implant 1 may receive a load, leading to healthy fusion. The vertical load in the human spine is transferred through the peripheral cortex of the vertebral bodies. By implanting an apophyseal-supporting implant 1 the natural biomechanics may be better preserved than for conventional devices.
The top 10 and bottom 20 surfaces of the implant 1 generally contact vertebral end-plates, for example, at the peripheral apophyseal rim, where the end-plates are the strongest and least likely to subside. It is preferred that the top 10 and bottom 20 surfaces do not include teeth, spikes, or ridges that may score or damage the bone. Rather, the top 10 and bottom 20 surfaces include a bioactive surface roughening 80, also referred to as a roughened surface topography 80, which helps to facilitate osteointegration (e.g., formation of a direct structural and functional interface between the artificial implant and living bone or soft tissue) with the surrounding living bone. Without intending to be limited to any particular theory or mechanism of action, it is believed that these cells attach more readily to relatively rough surfaces rather than smooth surfaces. In this manner, a surface may be bioactive due to its ability to stimulate cellular attachment and osteointegration.
In addition one or more surfaces of the anterior side 40, posterior side 50, or lateral sides 30 may also comprise a bioactive surface roughening 80, for example, as shown in
The bioactive surface roughening 80 (on any surface or portion of the implant) may be comprised of macro features, micro features, and nano features. For example, the bioactive surface roughening 80 may be obtained by combining separate macro processing, micro processing, and nano processing steps. Macro features include dimensions measured in millimeters (mm). Micro features comprise dimensions measured in microns (μm). Nano features include dimensions measured in nanometers (nm).
The shapes of the frictional surface protrusions of the bioactive surface roughening 80 may be formed using processes and methods commonly applied to remove metal during fabrication of implantable devices such as chemical, electrical, electrochemical, plasma, or laser etching; cutting and removal processes; casting; forging; machining; drilling; grinding; shot peening; abrasive media blasting (such as sand or grit blasting); and combinations of these subtractive processes. Additive processes such as welding, thermal, coatings, sputtering, and optical melt additive processes are also suitable. The resulting surfaces either can be random in the shape and location of the features or can have repeating patterns. This flexibility allows for the design and production of surfaces that resist motion induced by loading in specific directions that are beneficial to the installation process and resist the opposing forces that can be the result of biologic or patient activities such as standing, bending, or turning or as a result of other activities. The shapes of the surface features when overlapping increase the surface contact area but do not result in undercuts that generate a cutting or aggressively abrasive action on the contacting bone surfaces. Regular and repeating patterns are preferred.
These designed surfaces are composed of various sizes of features that, at the microscopic level, interact with the tissues and stimulate their natural remodeling and growth. At a larger scale these features perform the function of generating non-stressful friction that, when combined with a surgical technique that retains the most rigid cortical bone structures in the disc space, allow for a friction fit that does not abrade, chip, perforate, or compromise the critical endplate structures. The overlapping of the three feature sizes can be achieved using manufacturing processes that are completed sequentially and, therefore, do not remove or degrade the previous method.
The first step in the process may be mechanical (e.g., machining though conventional processes) or chemical bulk removal, for example, to generate macro features. The macro features may be of any suitable shape, for example, roughly spherical in shape, without undercuts or protruding tooth-like edges. Other shapes are possible, such as ovals, polygons (including rectangles), cones, triangles, and other shapes. These features may be at least partially overlapped with the next scale (micro) of features using either chemical or mechanical methods (e.g., AlO2 blasting) in predetermined patterns which also do not result in undercuts or protruding sharp edges. The third and final process step is completed through more mild (less aggressive) etching (e.g., HCl acid etching) that, when completed, generates surface features in both the micro and nano scales over both of the features generated by the two previous steps. The nano layer dictates the final chemistry of the implant material.
The macro features of the bioactive surface roughening 80 are relatively large features (e.g., on the order of millimeters). The macro features may be formed from subtractive techniques (e.g., mechanical or chemical bulk removal, for example) or additive techniques (e.g., deposition). Preferably, the macro features are formed by subtractive techniques, which remove portions of the surface (e.g., from the base material that was used to form the implant 1). Suitable subtractive techniques may include, for example, machining (e.g., machine tools, such as saws, lathes, milling machines, and drill presses, are used with a sharp cutting tool to physically remove material to achieve a desired geometry) or masked etching (e.g., portions of the surface are protected by a masking material which resists etching and an etching substance is applied to unmasked portions). The patterns may be organized in regular repeating patterns, and optionally overlap each other. In a preferred embodiment, the macro features may be formed in three, sequential steps.
The macro features may be produced by a heavy masked etching process, for example. Before etching, the surface may be cleaned and optionally blasted with an abrasive (e.g., alumina) in the areas to be chemically textured. Certain areas may be masked in a pattern. The surface may then be chemically milled, for example, using a composition comprising hydrofluoric acid. The maskant and chemical milling may be repeated any number of times necessary to produce the desired pattern and etching depth. After the final etching process, the maskant may be removed and the part may be cleaned. The surface may also be passivated, for example, using an aqueous solution comprising nitric acid. The part may be cleaned and rinsed with water.
The macro features may be formed, for example, using three cut patterns. Specifically, a first cut pattern of the macro features may be formed. The “cut 1” features of the first cut pattern may cover about 20% of the total area of the surface, for example, leaving about 80% of the original surface remaining. The range of these percentages may be about ±20%, preferably ±10%, and more preferably about ±5%. The “cut 1” features of the first cut pattern do not have any undercuts. In one embodiment, these “cut 1” features have the smallest diameter and greatest depth of the macro features that are formed during the sequential steps.
A second cut pattern of the macro features may be formed in the surface. Together, the “cut 1” features of the first cut pattern and the “cut 2” features of the second cut pattern may cover about 85% of the total area of the surface, for example, leaving about 15% of the original surface remaining. The range of these percentages may be about ±10% and preferably ±5%. In an embodiment of the invention, these “cut 2” features have both a diameter and a depth between those of the “cut 1” and “cut 3” features of the macro features that are formed during the first and third steps of the process of forming the macro features of the bioactive surface roughening 80.
A third cut pattern of the macro features may be formed in the surface. Together, the “cut 1” features of the first cut pattern, the “cut 2” features of the second cut pattern, and the “cut 3” features of the third cut pattern may cover about 95% of the total area of the surface, for example, leaving about 5% of the original surface remaining. The range of these percentages may be about ±1%. In an embodiment of the invention, these “cut 3” features may have the largest diameter and least depth of the macro features that are formed during the sequential process steps.
After the macro features are formed, additional process steps may be sequentially applied, in turn, to form the micro surface features (e.g., on the order of micrometers) of the bioactive surface roughening 80. The micro features may also be formed from subtractive techniques (e.g., mechanical or chemical bulk removal, for example) or additive techniques (e.g., deposition). Preferably, the micro features are also formed by subtractive techniques.
In an exemplary embodiment, the micro features are removed by masked or unmasked etching, such as acid etching. For example, portions of the surface, including portions of the surface exposed by the macro step(s) described above, may be exposed to abrasive blasting, chemical etching, or both. In an exemplary embodiment, the micro process includes an acid etching, with a strong acid, such as hydrochloric acid (HCl), hydroiodic acid (HI), hydrobromic acid (HBr), hydrofluoric acid (HF), perchloric acid (HClO4), nitric acid (HNO3), and sulfuric acid (H2SO4). Preferably, the acid etching uses an aqueous solution comprising hydrochloric acid. The etching process may be repeated a number of times as necessitated by the amount and nature of the irregularities required for any particular application. Control of the strength of the etchant material, the temperature at which the etching process takes place, and the time allotted for the etching process allows fine control over the resulting surface produced by the process. The number of repetitions of the etching process can also be used to control the surface features.
By way of example, an etchant mixture of at least one of nitric acid and hydrofluoric acid may be repeatedly applied to a titanium surface to produce an average etch depth of about 0.53 mm. In another example, chemical modification of titanium can be achieved using at least one of hydrofluoric acid, hydrochloric acid, and sulfuric acid. In a dual acid etching process, for example, the first exposure is to hydrofluoric acid and the second is to a hydrochloric acid and sulfuric acid mixture. Chemical acid etching alone may enhance osteointegration without adding particulate matter (e.g., hydroxyapatite) or embedding surface contaminants (e.g., grit particles).
In one embodiment, the micro features are created by abrasive or grit blasting, for example, by applying a stream of abrasive material (such as alumina and sand) to the surface. In an exemplary embodiment, the micro features are created, at least partially, with an aqueous hydrochloric acid etching step and at least partially with an AlO2 blasting step. Patterns may be organized in regular repeating patterns and optionally overlap each other.
After the micro features are formed, it is possible that less than about 3% of the original surface remains. The range of that percentage may be about ±1%.
After the macro features and micro features are formed, additional process steps may be sequentially applied, in turn, to form the nano surface features (e.g., on the order of nanometers) of the bioactive surface roughening 80. The nano features may also be formed from subtractive techniques (e.g., mechanical or chemical bulk removal, for example) or additive techniques (e.g., deposition). Preferably, the nano features are also formed by subtractive techniques.
In an exemplary embodiment, the nano features are removed by masked or unmasked etching. For example, portions of the surface, including portions of the surface exposed by the macro and micro steps described above, may be exposed to a chemical etching. In an exemplary embodiment, the nano process also includes an acid etching, with a strong or weak acid, such as hydrochloric acid (HCl), hydroiodic acid (HI), hydrobromic acid (HBr), hydrofluoric acid (HF), perchloric acid (HClO4), nitric acid (HNO3), and sulfuric acid (H2SO4). The acid etching process for the nano step is preferably less aggressive than the acid etching process in the macro or micro steps. In other words, a less acidic, mild, or more diluted acid may be selected. In an exemplary embodiment, the nano features are created, at least partially, with an aqueous hydrochloric acid etching step.
As an example, the nano features (or micro features) may be formed by preparing an acid solution comprising hydrochloric acid, water, and titanium; applying the acid solution to the surface; removing the acid solution by rinsing with water; and heating and subsequently cooling the surface.
The acid solution may be prepared using any suitable techniques known in the art. For example, the acid solution may be prepared by combining hydrochloric acid and water, simultaneously or sequentially. The aqueous hydrochloric acid solution may optionally be heated, for example, to a temperature of about 150-250° F. (66-121° C.), preferably about 200-210° F. (93-99° C.), and most preferably about 205° F. (96° C.). The titanium may be seeded (e.g., added) in the aqueous hydrochloric acid solution or may already be present from titanium previously removed from at least one surface of the implant, for example, in a continuous manufacturing process. The solution may optionally be cooled. The acid solution may comprise a concentration of 20-40% hydrochloric acid, preferably about 25-31% hydrochloric acid, and more preferably about 28% hydrochloric acid, based on the total weight of the solution.
It is contemplated that the nano features may also be created by the abrasive or grit blasting, for example, described for the micro processing step. Patterns may be organized in regular repeating patterns and optionally overlap each other. The nano features may also be achieved by tumble finishing (e.g., tumbling). The tumbling process may be wet (e.g., with a lubricant) or dry. After the nano features are formed, it is possible that less than about 1% of the original surface remains.
Any or each of the steps, including the macro, micro, or nano processing steps, may be accompanied by a cleaning step. In addition, the part may be cleaned once the processing steps are complete. For example, the part may be washed in an aqueous environment under agitation and heat with or without a detergent. Following washing, the part may be dried, for example with hot air, heating in a dry oven, or both.
The process steps described in this document can be adjusted to create a mixture of depths, diameters, feature sizes, and other geometries suitable for a particular implant application. The orientation of the pattern of features can also be adjusted. Such flexibility is desirable, especially because the ultimate pattern of the bioactive surface roughening 80 of the implant 1 should be oriented in opposition to the biologic forces on the implant 1 and to the insertion direction.
Several separate parameters can be used to characterize the surface roughness. Among those parameters are the average amplitude, Ra; the maximum peak-to-valley height, Rmax; and the mean spacing, Sm. Surface roughness may be measured using a laser profilometer or other standard instrumentation.
In addition to the parameters Ra, Rmax, and Sm mentioned above, at least two other parameters can be used to characterize the roughness of an implant surface. In summary, the five parameters are: (1) average amplitude, Ra; (2) average peak-to-valley roughness, Rz; (3) maximum peak-to-valley height, Rmax; (4) total peak-to-valley of waviness profile, Wt; and (5) mean spacing, Sm.
Average Amplitude Ra. Ra comprises an arithmetic average height. Mathematically, Ra may be computed as the average distance between each roughness profile point and the mean line. In
In mathematical terms, this process can be represented by the following Formula I:
Average Peak-to-Valley Roughness Rz. The average peak-to-valley roughness, Rz, is defined by the ISO and ASME 1995 and later. Rz is based on one peak and one valley per sampling length. The RzDIN value is based on the determination of the peak-to-valley distance in each sampling length. These individual peak-to-valley distances are averaged, resulting in the RzDIN value, as illustrated in
Maximum Peak-to-Valley Height Rmax. The maximum peak-to-valley height, Rmax, comprises the maximum peak-to-valley distance in a single sampling length—as illustrated in
Total Peak-to-Valley of Waviness Profile Wt. The total peak-to-valley of waviness profile (over the entire assessment length) is illustrated in
Mean Spacing Sm. The mean spacing, Sm, comprises the average spacing between positive mean line crossings. The distance between each positive (upward) mean line crossing is determined and the average value is calculated, as illustrated in
The parameters Sm, Rmax, and Ra can be used to define the surface roughness following formation of each of the three types of features macro, micro, and nano. Such data are provided in Tables 1-3.
The macro features for each of the three parameters may comprise the following preferred ranges (all measurements in microns). In some aspects, the macro mean spacing, Sm, is about 400 to about 2000 micrometers. More preferably, the macro mean spacing is about 750 to about 1750 micrometers, and more preferably, the macro mean spacing is about 1000 to about 1500 micrometers. In some aspects, the macro mean spacing is about 500 to about 1000 micrometers, about 600 to about 900 micrometers, about 700 to about 1000 micrometers, about 750 to about 1200 micrometers, about 800 to about 1300 micrometers, about 900 to about 1300 micrometers, about 1000 to about 1300 micrometers, about 1100 to about 1300 micrometers, about 1100 to about 1400 micrometers, about 1150 to about 1250 micrometers, about 1150 to about 1350 micrometers, about 1200 to about 1500 micrometers, or about 1200 to about 1400 micrometers. In some aspects, the macro peak-to-valley height, Rmax, is about 40 to about 500 micrometers. More preferably, the macro peak-to-valley height is about 150 to about 400 micrometers, and more preferably, about 250 to about 300 micrometers. In some aspects, the macro mean peak-to valley height is about 100 to about 450 micrometers, about 200 to about 400 micrometers, about 200 to about 300 micrometers, about 260 to about 280 micrometers, about 250 to about 350 micrometers, about 260 to about 320 micrometers, or about 270 to about 300 micrometers. In some aspects, the macro average amplitude, Ra, is about 20 to about 200 micrometers. More preferably, the macro average amplitude is about 50 to about 150 micrometers, and more preferably about 100 to about 120 micrometers. In some aspects, the macro average amplitude is about 80 to about 180 micrometers, about 90 to about 160 micrometers, about 90 to about 140 micrometers, about 100 to about 150 micrometers, about 100 to about 130 micrometers, about 105 to about 125 micrometers, or about 105 to about 115 micrometers.
The micro features for each of the three parameters may comprise the following preferred ranges (all measurements in microns). In some aspects, the micro mean spacing, Sm, is about 20 to about 400 micrometers. More preferably, the micro mean spacing is about 100 to about 300 micrometers, and more preferably, the macro mean spacing is about 200 to about 220 micrometers. In some aspects, the micro mean spacing is about 50 to about 350 micrometers, about 75 to about 350 micrometers, about 75 to about 300 micrometers, about 100 to about 325 micrometers, about 100 to about 250 micrometers, about 120 to about 220 micrometers, about 150 to about 250 micrometers, about 180 to about 240 micrometers, about 190 to about 230 micrometers, or about 205 to about 215 micrometers. In some aspects, the micro peak-to-valley height, Rmax, is about 2 to about 40 micrometers. More preferably, the micro peak-to-valley height is about 5 to about 25 micrometers, and more preferably, about 6 to about 16 micrometers. In some aspects, the micro mean peak-to valley height is about 0.5 to about 50 micrometers, about 1 to about 45 micrometers, about 1 to about 40 micrometers, about 1 to about 30 micrometers, about 1 to about 20 micrometers, about 1 to about 15 micrometers, about 2 to about 50 micrometers, about 2 to about 30 micrometers, about 2 to about 25 micrometers, about 3 to about 40 micrometers, about 3 to about 30 micrometers, about 4 to about 40 micrometers, about 4 to about 30 micrometers, about 5 to about 40 micrometers, about 5 to about 30 micrometers, about 7 to about 20 micrometers, about 7 to about 15 micrometers, about 8 to about 14 micrometers, or about 9 to about 13 micrometers. In some aspects, the micro average amplitude, Ra, is about 1 to about 20 micrometers. More preferably, the micro average amplitude is about 1 to about 10 micrometers, and more preferably about 3 to about 7 micrometers. In some aspects, the micro average amplitude is about 0.5 to about 30 micrometers, about 0.5 to about 25 micrometers, about 1 to about 15 micrometers, about 1 to about 10 micrometers, about 1 to about 9 micrometers, about 1 to about 7 micrometers, about 2 to about 9 micrometers, or about 4 to about 7 micrometers.
The nano features for each of the three parameters may comprise the following preferred ranges (all measurements in microns). In some aspects, the nano mean spacing, Sm, is about 0.5 to about 20 micrometers. More preferably, the nano mean spacing is about 5 to about 15 micrometers, and more preferably, the macro mean spacing is about 8 to about 12 micrometers. In some aspects, the nano mean spacing is about 0.1 to about 30 micrometers, about 0.25 to about 25 micrometers, about 0.5 to about 15 micrometers, about 0.5 to about 13 micrometers, about 1 to about 250 micrometers, about 1 to about 20 micrometers, about 1 to about 150 micrometers, about 2 to about 18 micrometers, about 2 to about 12 micrometers, about 7 to about 14 micrometers, or about 9 to about 11.5 micrometers. In some aspects, the nan peak-to-valley height, Rmax, is about 0.2 to about 2 micrometers. More preferably, the nano peak-to-valley height is about 0.5 to about 1.5 micrometers, and more preferably, about 0.8 to about 1.4 micrometers. In some aspects, the nano mean peak-to valley height is about 0.05 to about 5 micrometers, about 0.1 to about 3 micrometers, about 0.1 to about 2 micrometers, about 0.1 to about 1.5 micrometers, about 0.1 to about 0.4 micrometers, about 0.2 to about 3 micrometers, about 0.2 to about 2.5 micrometers, about 0.2 to about 1.8 micrometers, about 0.6 to about 1.6 micrometers, about 0.7 to about 1.5 micrometers, or about 0.9 to about 1.3 micrometers. In some aspects, the nano average amplitude, Ra, is about 0.01 to about 1 micrometers. More preferably, the nano average amplitude is about 0.05 to about 0.75 micrometers, and more preferably about 0.3 to about 0.7 micrometers. In some aspects, the nano average amplitude is about 0.005 to about 2 micrometers, about 0.005 to about 1.5 micrometers, about 0.01 to about 0.75 micrometers, about 0.01 to about 1.1 micrometers, about 0.01 to about 0.9 micrometers, about 0.01 to about 0.07 micrometers, about 0.025 to about 0.75 micrometers, or about 0.04 to about 0.6 micrometers.
The implant 1 may be used in accordance with a corpectomy of vertebral body replacement procedure. The damaged or diseased portion of vertebral bone is removed, thereby forming a channel in one or more vertebrae (
The invention is not limited to the embodiments described and exemplified above, but is capable of variation and modification within the scope of the appended claims.
This application is a divisional of U.S. patent application Ser. No. 14/306,460 filed on Jun. 17, 2014, which is incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3650861 | Angell | Mar 1972 | A |
3891456 | Hohman et al. | Jun 1975 | A |
3933961 | Burns | Jan 1976 | A |
4116755 | Coggins et al. | Sep 1978 | A |
4314876 | Kremer et al. | Feb 1982 | A |
4414039 | Thoma | Nov 1983 | A |
4540465 | Coggins et al. | Sep 1985 | A |
4588480 | Thoma | May 1986 | A |
4634603 | Gruss et al. | Jan 1987 | A |
4644942 | Sump | Feb 1987 | A |
4673409 | Van Kampen | Jun 1987 | A |
4803098 | Henri et al. | Feb 1989 | A |
4818559 | Hama | Apr 1989 | A |
4818572 | Shimamune et al. | Apr 1989 | A |
4834756 | Kenna | May 1989 | A |
4846837 | Kurze et al. | Jul 1989 | A |
4863475 | Andersen et al. | Sep 1989 | A |
4900398 | Chen | Feb 1990 | A |
5100508 | Yoshida et al. | Mar 1992 | A |
5108432 | Gustavson | Apr 1992 | A |
5201766 | Georgette | Apr 1993 | A |
5246530 | Bugle et al. | Sep 1993 | A |
5258098 | Wagner et al. | Nov 1993 | A |
5411629 | Warfield | May 1995 | A |
5456723 | Steinemann | Oct 1995 | A |
5571188 | Ellingsen et al. | Nov 1996 | A |
5603338 | Beaty | Feb 1997 | A |
5639536 | Yamazaki et al. | Jun 1997 | A |
5787965 | Sterett et al. | Aug 1998 | A |
5705082 | Hinson | Oct 1998 | A |
5922029 | Wagner et al. | Jul 1999 | A |
6033582 | Lee et al. | Mar 2000 | A |
6068043 | Clark | May 2000 | A |
6096107 | Caracostas et al. | Aug 2000 | A |
6193762 | Wagner et al. | Feb 2001 | B1 |
6491723 | Beaty | Dec 2002 | B1 |
6620332 | Amrich | Sep 2003 | B2 |
6652765 | Beaty | Nov 2003 | B1 |
6736849 | Li et al. | May 2004 | B2 |
6810939 | Roche et al. | Nov 2004 | B2 |
6911249 | Wagner et al. | Jun 2005 | B2 |
7048870 | Ellingsen et al. | May 2006 | B1 |
7067169 | Liu et al. | Jun 2006 | B2 |
7079914 | Berggren | Jul 2006 | B2 |
7087085 | Steinemann et al. | Aug 2006 | B2 |
7144428 | Anitua | Dec 2006 | B2 |
7166129 | Michelson | Jan 2007 | B2 |
7241313 | Unwin et al. | Jul 2007 | B2 |
7368065 | Yang et al. | May 2008 | B2 |
7374642 | Deutchman et al. | May 2008 | B2 |
7445640 | Despres, III et al. | Nov 2008 | B2 |
7497876 | Tuke et al. | Mar 2009 | B2 |
7501073 | Wen et al. | Mar 2009 | B2 |
7537664 | O'Neill et al. | May 2009 | B2 |
7615078 | White et al. | Nov 2009 | B2 |
7648727 | Hossainy et al. | Jan 2010 | B2 |
7662190 | Steinemann et al. | Feb 2010 | B2 |
7704225 | Kantrowitz | Apr 2010 | B2 |
7771774 | Berckmans, III et al. | Aug 2010 | B2 |
7824462 | Webster et al. | Nov 2010 | B2 |
7901462 | Yang et al. | Mar 2011 | B2 |
7951285 | Zipprish | May 2011 | B2 |
7972648 | Berckmans, III et al. | Jul 2011 | B2 |
8052743 | Weber et al. | Nov 2011 | B2 |
8277577 | Garcia Saban et al. | Oct 2012 | B2 |
8309162 | Charlton et al. | Nov 2012 | B2 |
8334044 | Myung et al. | Dec 2012 | B2 |
8350186 | Jones et al. | Jan 2013 | B2 |
8399008 | Webster et al. | Mar 2013 | B2 |
8409655 | Uibel et al. | Apr 2013 | B2 |
8414908 | Jin et al. | Apr 2013 | B2 |
8444914 | Fecher et al. | May 2013 | B2 |
8486319 | Victor et al. | Jul 2013 | B2 |
8590157 | Kruth et al. | Nov 2013 | B2 |
8632836 | Fredriksson et al. | Jan 2014 | B2 |
8632843 | Andersson et al. | Jan 2014 | B2 |
8641418 | Mayfield et al. | Feb 2014 | B2 |
8679517 | Palmaz | Mar 2014 | B2 |
8696759 | Tong et al. | Apr 2014 | B2 |
8778443 | Uckelmann et al. | Jul 2014 | B2 |
8808385 | Smith et al. | Aug 2014 | B1 |
8814939 | Ullrich, Jr. et al. | Aug 2014 | B2 |
8843229 | Vanasse et al. | Sep 2014 | B2 |
9028584 | Wong | May 2015 | B2 |
9044528 | Esat et al. | Jun 2015 | B2 |
9125756 | Ullrich, Jr. | Sep 2015 | B2 |
9135374 | Jones et al. | Sep 2015 | B2 |
9149989 | Uckelmann | Oct 2015 | B2 |
9174390 | Lechmann et al. | Nov 2015 | B2 |
9192475 | Chaput et al. | Nov 2015 | B2 |
9237950 | Hensley et al. | Jan 2016 | B2 |
9249055 | Laughner et al. | Feb 2016 | B2 |
9421053 | Kennedy et al. | Aug 2016 | B2 |
9775711 | Li et al. | Oct 2017 | B2 |
9848995 | Ullrich, Jr. et al. | Dec 2017 | B2 |
20020156529 | Li et al. | Oct 2002 | A1 |
20020173854 | Amrich | Nov 2002 | A1 |
20030125739 | Bagga et al. | Jul 2003 | A1 |
20030181980 | Berry et al. | Sep 2003 | A1 |
20040049270 | Gewirtz | Mar 2004 | A1 |
20040134886 | Wagner et al. | Jul 2004 | A1 |
20040153154 | Dinkelacker | Aug 2004 | A1 |
20040167632 | Wen et al. | Aug 2004 | A1 |
20040167633 | Wen et al. | Aug 2004 | A1 |
20040265780 | Robb et al. | Dec 2004 | A1 |
20050062033 | Ichihara et al. | Mar 2005 | A1 |
20050147942 | Hall | Jul 2005 | A1 |
20050161120 | Inagaki et al. | Jul 2005 | A1 |
20050221258 | Hall | Oct 2005 | A1 |
20060004466 | Glocker et al. | Jan 2006 | A1 |
20060100716 | Lerf | May 2006 | A1 |
20060190079 | Istephanous et al. | Aug 2006 | A1 |
20060219661 | Towse et al. | Oct 2006 | A1 |
20060229715 | Istephanous | Oct 2006 | A1 |
20060235534 | Gertzman et al. | Oct 2006 | A1 |
20060241760 | Randall | Oct 2006 | A1 |
20070166349 | White | Jul 2007 | A1 |
20070203584 | Bandyioadhyay et al. | Aug 2007 | A1 |
20070213832 | Wen | Sep 2007 | A1 |
20070233248 | Schwab et al. | Oct 2007 | A1 |
20070259427 | Storey et al. | Nov 2007 | A1 |
20080014243 | Ellingsen et al. | Jan 2008 | A1 |
20080154378 | Pelo | Jun 2008 | A1 |
20080160259 | Nielson et al. | Jul 2008 | A1 |
20080195218 | Jones | Aug 2008 | A1 |
20080208351 | Besenbacher et al. | Aug 2008 | A1 |
20080261178 | Homann | Oct 2008 | A1 |
20080262623 | Bagga et al. | Oct 2008 | A1 |
20090076613 | Biedermann et al. | Mar 2009 | A1 |
20090088853 | Ogilvie et al. | Apr 2009 | A1 |
20090132048 | Denzer | May 2009 | A1 |
20090283701 | Ogawa | Nov 2009 | A1 |
20090312842 | Burase et al. | Dec 2009 | A1 |
20100021865 | Uckelmann et al. | Jan 2010 | A1 |
20100076559 | Bagga et al. | Mar 2010 | A1 |
20100094426 | Grohowski, Jr. et al. | Apr 2010 | A1 |
20100137990 | Apatsidis et al. | Jun 2010 | A1 |
20100167020 | Jones et al. | Jul 2010 | A1 |
20100168798 | Clineff et al. | Jul 2010 | A1 |
20100173264 | Fredriksson et al. | Jul 2010 | A1 |
20100174382 | Gretzer et al. | Jul 2010 | A1 |
20100114303 | Su et al. | Aug 2010 | A1 |
20100204777 | Storey et al. | Aug 2010 | A1 |
20100218854 | Garcia Saban et al. | Sep 2010 | A1 |
20100268227 | Tong et al. | Oct 2010 | A1 |
20100303722 | Jin et al. | Dec 2010 | A1 |
20110009965 | Ankem | Jan 2011 | A1 |
20110014081 | Jones et al. | Jan 2011 | A1 |
20110033661 | Oawa | Feb 2011 | A1 |
20110035020 | Laughner et al. | Feb 2011 | A1 |
20110089041 | Gupta et al. | Apr 2011 | A1 |
20110151026 | Hansson et al. | Jun 2011 | A1 |
20110190888 | Bertele | Aug 2011 | A1 |
20110190902 | Tong et al. | Aug 2011 | A1 |
20110190904 | Lechmann et al. | Aug 2011 | A1 |
20110233169 | Mayfield et al. | Sep 2011 | A1 |
20110282454 | Ullrich, Jr. et al. | Nov 2011 | A1 |
20110287223 | Victor et al. | Nov 2011 | A1 |
20110318835 | Chen et al. | Dec 2011 | A1 |
20120009341 | Noh et al. | Jan 2012 | A1 |
20120022650 | Gilbert et al. | Jan 2012 | A1 |
20120064290 | Esat et al. | Mar 2012 | A1 |
20120136396 | Baker et al. | May 2012 | A1 |
20120239150 | Ullrich, Jr. et al. | Sep 2012 | A1 |
20120276336 | Malshe et al. | Nov 2012 | A1 |
20120303127 | Ullrich, Jr. et al. | Nov 2012 | A1 |
20120308837 | Schlechtrimen et al. | Dec 2012 | A1 |
20120310365 | Chaput et al. | Dec 2012 | A1 |
20120312778 | Ullrich, Jr. et al. | Dec 2012 | A1 |
20120312779 | Patterson et al. | Dec 2012 | A1 |
20120316650 | Ullrich, Jr. et al. | Dec 2012 | A1 |
20120316651 | Ullrich, Jr. et al. | Dec 2012 | A1 |
20120316653 | Ullrich, Jr. | Dec 2012 | A1 |
20130006363 | Ullrich, Jr. et al. | Jan 2013 | A1 |
20130030544 | Studer | Jan 2013 | A1 |
20130045360 | Ibacache et al. | Feb 2013 | A1 |
20130056912 | O'Neil et al. | Mar 2013 | A1 |
20130059946 | Zhu et al. | Mar 2013 | A1 |
20130110243 | Patterson | May 2013 | A1 |
20130123925 | Patterson | May 2013 | A1 |
20130204384 | Hensley et al. | Aug 2013 | A1 |
20130244003 | Yoo et al. | Sep 2013 | A1 |
20130248487 | Mayfield et al. | Sep 2013 | A1 |
20130261764 | Guerra et al. | Oct 2013 | A1 |
20130264749 | Jones et al. | Oct 2013 | A1 |
20130292357 | Ullrich, Jr. et al. | Nov 2013 | A1 |
20130302427 | Arvidsson et al. | Nov 2013 | A1 |
20130302509 | McEntire | Nov 2013 | A1 |
20130306591 | Ullrich, Jr. et al. | Nov 2013 | A1 |
20130310938 | Sournac et al. | Nov 2013 | A1 |
20130330688 | Hedrick et al. | Dec 2013 | A1 |
20140025181 | Vanasse et al. | Jan 2014 | A1 |
20140034368 | Klamminger et al. | Feb 2014 | A1 |
20140048981 | Crump et al. | Feb 2014 | A1 |
20140106144 | Wong | Apr 2014 | A1 |
20140172111 | Lang et al. | Jun 2014 | A1 |
20140195001 | Grohowski, Jr. | Jul 2014 | A1 |
20140195005 | McKay | Jul 2014 | A1 |
20140277517 | Winslow | Sep 2014 | A1 |
20140343687 | Jennissen | Nov 2014 | A1 |
20150012109 | Moreau et al. | Jan 2015 | A1 |
20150030493 | Scott et al. | Jan 2015 | A1 |
20150033543 | Markwardt | Feb 2015 | A1 |
20150045903 | Neal | Feb 2015 | A1 |
20150093719 | Beeby | Apr 2015 | A1 |
20150209094 | Anderson | Jul 2015 | A1 |
20150320466 | Kennedy et al. | Nov 2015 | A1 |
20150320525 | Lin et al. | Nov 2015 | A1 |
20150335434 | Patterson et al. | Nov 2015 | A1 |
20170071744 | Bali et al. | Mar 2017 | A1 |
20170165790 | McCarthy et al. | Jun 2017 | A1 |
20170173225 | Troxel | Jun 2017 | A1 |
20170182222 | Paddock et al. | Jun 2017 | A1 |
20170239052 | Wainscott et al. | Aug 2017 | A1 |
20170281827 | Baker | Oct 2017 | A1 |
20170290666 | Behzadi | Oct 2017 | A1 |
20170290667 | Behzadi | Oct 2017 | A1 |
20180200062 | Meyenhofer et al. | Jul 2018 | A1 |
20180326493 | Gallagher | Nov 2018 | A1 |
20180333782 | Gallagher et al. | Nov 2018 | A1 |
20190142574 | Quiros et al. | May 2019 | A1 |
20190231535 | Gallagher | Aug 2019 | A1 |
Number | Date | Country |
---|---|---|
2597249 | Aug 2006 | CA |
1392799 | Jan 2003 | CN |
1638820 | Jul 2005 | CN |
101340934 | Jan 2009 | CN |
101634025 | Jan 2010 | CN |
101720209 | Jun 2010 | CN |
101848683 | Sep 2010 | CN |
102300518 | Dec 2011 | CN |
101686862 | Aug 2014 | CN |
0947605 | Oct 1999 | EP |
1440669 | Jul 2004 | EP |
1449544 | Aug 2004 | EP |
2386274 | Nov 2011 | EP |
1947217 | May 2012 | EP |
2523814 | Mar 2014 | GB |
H10130757 | May 1998 | JP |
2001000452 | Jan 2001 | JP |
2003521973 | Jul 2003 | JP |
2008-536535 | Sep 2008 | JP |
2009526614 | Jul 2009 | JP |
2009189817 | Aug 2009 | JP |
2011092736 | May 2011 | JP |
2011194099 | Oct 2011 | JP |
2015-512762 | Apr 2015 | JP |
2015512762 | Apr 2015 | JP |
WO2004008983 | Jan 2004 | WO |
WO2006102347 | Sep 2006 | WO |
WO2007045471 | Apr 2007 | WO |
WO2011094604 | Aug 2011 | WO |
WO2011094748 | Aug 2011 | WO |
WO2013126407 | Aug 2013 | WO |
WO2013167904 | Nov 2013 | WO |
WO2014018325 | Jan 2014 | WO |
WO2014028505 | Feb 2014 | WO |
WO2014154901 | Oct 2014 | WO |
WO2015132325 | Sep 2015 | WO |
2015157703 | Oct 2015 | WO |
WO2015164982 | Nov 2015 | WO |
WO2017053480 | Mar 2017 | WO |
WO2017062397 | Apr 2017 | WO |
2017087927 | May 2017 | WO |
2017087944 | May 2017 | WO |
WO2017091657 | Jun 2017 | WO |
WO2017177046 | Oct 2017 | WO |
Entry |
---|
Examiner's Report for Canadian Application No. 2,951,709 dated Jul. 29, 2021, 4 pages. |
International Search Report and Written Opinion issued in related application PCT/US2015/036118 dated Sep. 23, 2015. |
Examination Report No. 1, dated Feb. 13, 2019, for Australian Patent Application No. 2015277294. |
Dong Cong, et al., “Research on the surface morphology and biocompatibility of laser rapid forming titanium implants,” Chinese Journal of Oral Implantology, 2013, vol. 18, No. 4, pp. 215-218. |
Koch, Carl C., (2007). “Nanostructured Materials—Processing, Properties, and Applications,” (2nd Edition)—5.3.4.1 Hot Pressing (pp. 210-211). William Andrew Publishing. |
Hot Isostatic Pressing (HIP) Isostatic Pressing Association, http://ipa-web.org/about-ip/hip.html, Oct. 16, 2016 (IPA). |
The National Institute for Occupational Safety and Health (NIOSH), “Preventing Silicosis and Deaths from Sandblasting,” Center for Disease Control and Prevention, Aug. 1992, 13 pages. |
Matteson, et al., “Assessing the hierarchical structure of titanium implant surfaces,” May 7, 2015, Journal of Biomedical Materials Research B: Applied Biomaterials, vol. 00b, Issue 00. |
Yavari, et al., “Bone regeneration performance of surface-treated porous titanium,” Biomaterials vol. 35, Issue 24, Aug. 2014, pp. 6172-6181. |
Yan, Fuyao, et al., “Grain Structure Control of Additively Manufactured Metallic Materials,” Materials 2017, 10, 1260, Nov. 2, 2017, 11 pages. |
Fernandez-Zelaia, et al., “Crystallographic texture control in electron beam additive manufacturing via conductive manipulation,” Materials and Design, vol. 195, Jul. 31, 2020, pp. 1-10. |
Thijs, et al., “A study of the microstructural evolution during selective laser melting of Ti—6Al—4V,” Acta Materialia, vol. 58, Issue 9, Mar. 16, 2010, pp. 3303-3312. |
M. Thone, et al., “Influence of heat-treatment on selective laser melting products—e.g. Ti6A 14V,” SFF Symposium, Aug. 22, 2012, pp. 492-498, Retrieved from the Internet: URL:https://sffsymposium.engr.utexas.edu/Manuscripts/2012/2012-38-Thoene.pdf. |
Tammas-Williams Samuel et al: “The Effectiveness of Hot Isostatic Pressing for Closing Porosity in Titanium Parts Manufactured by Selective Electron Beam Melting”, Metallurgical and Materials Transactions A: Physical Metallurgy & Materials Science, ASM International, Materials Park, OH, US, Mar. 16, 2016, vol. 47, No. 5, pp. 1939-1946. |
Boyan et al., “Implant Surface Design Regulates Mesenchymal Stem Cell Differentiation and Maturation”, Advances in Dental Research, 2016, 28(1), pp. 10-17. |
Cheng et al., “Additively Manufactured 3D Porous Ti—6Al—4V Constructs Mimic Trabecular Bone Structure and Regulate Osteoblast Proliferation, Differentiation and Local Factor Production in a Porosity and Surface Roughness Dependent Manner”, Biofabrication, 6(4), 045007. |
Cheng et al., “Laser-Sintered Constructs with Bio-inspired Porosity and Surface Micro/Nano-Roughness Enhance Mesenchymal Stem Cell Differentiation and Matrix Mineralization In Vitro”, Calcif Tissue Int, 2016, 99(6), pp. 625-637. |
Cohen et al., “Novel Osteogenic Ti—6Al—4V Device For Restoration Of Dental Function In Patients With Large Bone Deficiencies: Design, Development, And Implementation”, Scientific Reports, 2016, 6(20493), pp. 1-12. |
Hyzy et al., “Novel Hydrophilic Nanostructured Microtexture on Direct Metal Laser Sintered Ti—6Al—4V Surfaces Enhances Osteoblast Response in Vitro and Osseointegration in a Rabbit Model”, J Biomed Mater Res A, 2016, 104 (8), pp. 2086-2098. |
Baek, W-Y, et al. “Positive Regulation of Adult Bone Formation by Osteoblast-Specific Transcription Factor Osterix”, Journal of Bone Mineral Research, Dec. 29, 2008, vol. 24, No. 6, pp. 1055-1065. |
Zhang, C., “Transcriptional regulation of bone formation by the osteoblast-specific transcription factor Osx”, Journal of Orthopaedic Surgery and Research, Jun. 15, 2010, vol. 5, No. 37. |
Tu et al., “Osterix Overexpression in Mesenchymal Stem cells Stimulates Healing of Critical-Sized Defects in Murine Calvarial Bone”, Tissue Engineering, Oct. 2007, vol. 13, No. 10, pp. 2431-2440. |
Leung, K.S. et al. “Plasma Bone-Specific Alkaline Phosphatase as an Indicator of Osteoblastic Activity”, Journal of Bone & Joint Surgery, Jul. 14, 1992, vol. 75, No. 2, pp. 288-292. |
Herrmann et al., “Different Kinetics of Bone Markers in Normal and Delayed Fracture Healing of Long Bones”, Clinical Chemistry, Dec. 2002, vol. 48, Issue 12, pp. 2263-2266. |
Borden M, et al., “The sintered microsphere matrix for bone tissue engineering: In vitro osteoconductivity studies”, Journal of Biomedical Materials Research, Dec. 2001, vol. 61, No. 3, pp. 421-429. |
Borden M, et al., “Tissue engineered microsphere-based matrices for bone repair: design and evaluation”, Biomaterials, Apr. 3, 2001, vol. 23, pp. 551-559. |
Borden M, et al., “Tissue-engineered bone formation in vivo using a novel sintered polymeric microsphere matrix”, Journal of Bone and Joint Surgery, Jan. 15, 2004, vol. 86, pp. 1200-1208. |
Datta et al., “Effect of bone extracellular matrix synthesized in vitro on the osteoblastic differentiation of marrow stromal cells”, Biomaterials, Jul. 21, 2004, vol. 26, No. 9, pp. 971-977. |
Bancroft et al., “Fluid flow increases mineralized matrix deposition in 3D perfusion culture of marrow stromal osteoblasts in a dose-dependent manner”, Proceedings of the National Academy of the Sciences of the U.S.A., Oct. 1, 2002, vol. 99, No. 20, pp. 12600-12605. |
Sikavitsas et al., “Influence of the in vitro culture period on the in vivo performance of cell/titanium bone tissue-engineered constructs using a rat cranial critical size defect model”, Journal of Biomedical Materials Research, Mar. 31, 2003, vol. 67, No. 3, pp. 944-951. |
“The Effects of Hot Isostatic Pressing of Platinum Alloy Castings on Mechanical Properties and Microstructures” Frye T, Johnson Matthey Technology Review, 2015, vol. 59, No. 3, pp. 207-217. |
Westfall, Kurtosis as Peakedness, 1905-2014. R.I.P., Am Stat. 2014; 68(3): 191-195 (Year: 2014). |
Astra Tech Dental, “Nanolevel topographic modifications on the OsseoSpeed surface,” http://shop.dentsplyimplants.us, Mar. 8, 2001. |
Eurcoating, “Additive Manufacturing: long-term specialist expertise in manufacturing implantable devices,” Additive Manufacturing, 2008, Eurocoating spa, Trento Italy, www.eurocoating.it. |
E-Manufacturing Solutions, “Additive Manufacturing in the Medical Field,” Medical, Mar. 2013, e-Manufacturing Solutions, Krailing/Munich Germany, www.eos.info. |
Guo, et al., “The effect of hydrofluoric acid treatment of TiO2 grit blasted titanium implants on adherent osteoblast gene expression in vitro and in vivo,” Biomaterials 28, Sep. 14, 2007, 5418-5425. |
He, et al., “Mechanical and Histomorphometric Evaluations of Rough Titanium Implants Treated with Hydrofluoric Acid/Nitric Acid Solution in Rabbit Tibia,” Int. J. Oral Maxillofac., Implants, Nov. 1, 2011; 26; 115-122. |
ipmd.net, “Powder Metallurgy Review,” 2012, ipmd.net, pp. 1-32, www.ipmd.net. |
Isa, et al., “Effects of Fluoride-Modified Titanium Surfaces on Osteoblast Proliferation and Gene Expression,” Int. J. Oral Maxillofac, Implants, 2006, 21:203-211. |
Lamolle, et al., “The effect of hydrofluoric acid treatment of titanium surface on nanostructural and chemical changes and the growth of MC3T3-E1 cells,” Biomaterials 30 (Nov. 20, 2008) 736-742. |
Layerwise, “Medical Application,” Layerwise, 2012, Belgium, www.layerwise.com, www.dentwise.eu. |
Meirelles, et al., “The Effect of Chemical and Nanotopographical Modifications on the Early Stages of Osseointegration,” Int. J. Oral Maxillofac, Implants 2008, 23, 641-647. |
Variola, et al., “Nanoscale surface modifications of medically relevant metals: state-of-the-art and perspectives,” Nanoscale, 2011, 2, 335-353. |
Wennerberg, A., et al., “Effects of titanium surface topography on bone integration: a systematic review,” Clin. Oral. Impl. Res. 20, (Suppl. 4), 2009, pp. 172-184. |
Wennerberg, et al., “Spontaneously formed nanostructures on titanium surfaces,” Clin. Oral. Impl. Res., 2012, 1-7. |
Anonymous: “Hot Isostatic pressing—Wikipedia,” Mar. 19, 2019 (Mar. 19, 2019), XP55571109; Retrieved from the Internet: URL:https://en.wikipedia.org/wiki/Hot_isostatic-pressing. |
Number | Date | Country | |
---|---|---|---|
20200289284 A1 | Sep 2020 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14306460 | Jun 2014 | US |
Child | 16867959 | US |